47.64 0.00 (0.00%)
After hours: 4:00PM EST
|Bid||47.73 x 1200|
|Ask||47.76 x 800|
|Day's Range||46.79 - 48.30|
|52 Week Range||32.33 - 61.23|
|Beta (3Y Monthly)||1.87|
|PE Ratio (TTM)||102.67|
|Earnings Date||Feb 25, 2020 - Mar 2, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.00|
Is FibroGen Inc (NASDAQ:FGEN) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus […]
FibroGen, Inc. (FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA). Roxadustat is included on the NRDL for the treatment of anemia in chronic kidney disease (CKD), covering patients who are non-dialysis-dependent (NDD) as well as those who are dialysis-dependent (DD). “Inclusion on the NRDL is a significant milestone and inflection point for the growth trajectory for roxadustat, as reimbursement provides affordability and access for patients on a national basis,” said Jim Schoeneck, Interim CEO, FibroGen.
NEW YORK, NY / ACCESSWIRE / November 15, 2019 / Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (FGEN). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. The investigation concerns whether FibroGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against FibroGen, Inc. on behalf of FibroGen stockholders.
SAN FRANCISCO, Nov. 13, 2019 -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors who have suffered significant losses to submit their loss now to learn if they.
Glancy Prongay & Murray LLP announces an investigation on behalf of FibroGen, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of FibroGen, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.
FibroGen (FGEN) delivered earnings and revenue surprises of 3.39% and 8.13%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Roxadustat Positive Pooled Phase 3 Efficacy and Cardiovascular Safety Data Presented Last Friday at American Society of Nephrology 2019 Kidney WeekPlan to Submit Roxadustat U.S..
Roxadustat cardiovascular safety comparable to placebo in non-dialysis dependent (NDD) patients, as assessed by Major Adverse Cardiovascular Events (MACE) and MACE+ Roxadustat.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ...
Incident dialysis was defined as those who initiated dialysis within 4 months before randomization to roxadustat or epoetin alfa. In this trial of 1,043 patients, believed to be the largest trial to date investigating an anemia medicine in the ID population, roxadustat achieved both primary efficacy endpoints.
NEW YORK, NY / ACCESSWIRE / November 6, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of FibroGen, Inc. ("FibroGen" or "the Company") ...
SAN FRANCISCO , Nov. 5, 2019 /PRNewswire/ -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors who have suffered significant losses to submit their loss now to learn if they qualify to recover ...